Dasatinib, marketed by Bristol Myers Squibb (BMS) under the brand name Sprycel, is a tyrosine kinase inhibitor used to treat certain types of leukemia. The patent landscape for dasatinib is complex, with multiple patents covering the drug itself, its manufacturing processes, and its uses [1].
When does the main patent for Sprycel expire?
The primary patent covering the composition of matter for dasatinib is expected to expire in 2027 [1]. However, this expiration date can be influenced by various factors, including patent extensions and potential legal challenges.
What other patents protect Sprycel?
Beyond the core composition of matter patent, BMS has secured numerous secondary patents related to dasatinib. These can include patents for specific crystalline forms of the drug, methods of manufacturing, and new therapeutic uses. These secondary patents can extend market exclusivity beyond the expiration of the initial patent [2]. Information on specific patent numbers and their expiration dates can be found on resources like DrugPatentWatch.com [1][2].
Who is challenging dasatinib patents?
Generic drug manufacturers often challenge existing patents to gain early market entry for their versions of a drug. While specific companies and the status of their challenges can change, the expiration and potential invalidation of dasatinib patents are of significant interest to generic competitors [2].
Can biosimilars or generics be made before patent expiry?
Generally, generic versions of small molecule drugs like dasatinib cannot legally enter the market until relevant patents expire or are invalidated. This contrasts with biologics, where biosimilars follow a different regulatory pathway. For dasatinib, generic entry is anticipated after the expiration of key patents, such as the composition of matter patent in 2027, provided no further legal protections or extensions are in place [1][2].
What is the clinical use of dasatinib?
Dasatinib is primarily indicated for the treatment of chronic myeloid leukemia (CML) in patients who are resistant or intolerant to prior therapies, as well as Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [3]. It works by inhibiting certain enzymes that are involved in cancer cell growth and proliferation [4].
What are the common side effects of dasatinib?
Patients taking dasatinib may experience a range of side effects. Common adverse reactions include fluid retention (edema), rash, diarrhea, headache, muscle pain, and fatigue. More serious side effects can include myelosuppression (low blood cell counts), cardiac issues, and bleeding events [3].
How does dasatinib compare to other CML treatments?
Dasatinib is one of several tyrosine kinase inhibitors available for CML treatment. It is often used when other TKIs, such as imatinib, have not been effective or have caused unacceptable side effects. Other TKIs for CML include nilotinib, bosutinib, and ponatinib, each with its own efficacy and side effect profile [3][4].
What is the regulatory status of dasatinib?
Sprycel (dasatinib) is approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its indicated uses in leukemia [3].
Sources:
1. https://drugpatentwatch.com/
2. https://drugpatentwatch.com/drugs/dasatinib
3. https://www.sprycel.com/
4. https://www.cancer.org/cancer/types/leukemia-chronic-myeloid/treatment/tkis.html